Nadav Kidron Esq.
Net Worth
Last updated:
What is Nadav Kidron Esq. net worth?
The estimated net worth of Mr. Nadav Kidron Esq. is at least $16,182,660 as of 16 Mar 2023. He owns shares worth $259,560 as insider, has earned $4,423,100 from insider trading and has received compensation worth at least $11,500,000 in Oramed Pharmaceuticals Inc..
What is the salary of Nadav Kidron Esq.?
Mr. Nadav Kidron Esq. salary is $1,150,000 per year as Pres, Chief Executive Officer & Executive Director in Oramed Pharmaceuticals Inc..
How old is Nadav Kidron Esq.?
Mr. Nadav Kidron Esq. is 51 years old, born in 1974.
What stocks does Nadav Kidron Esq. currently own?
As insider, Mr. Nadav Kidron Esq. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. (ORMP) | Pres, Chief Executive Officer & Executive Director | 126,000 | $2.06 | $259,560 |
What does Oramed Pharmaceuticals Inc. do?
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Nadav Kidron Esq. insider trading
Oramed Pharmaceuticals Inc.
Mr. Nadav Kidron Esq. has made 2 insider trades between 2015-2023, according to the Form 4 filled with the SEC. Most recently he purchased 26,000 units of ORMP stock worth $53,014 on 16 Mar 2023.
The largest trade he's ever made was exercising 220,000 units of ORMP stock on 9 Aug 2021. As of 16 Mar 2023 he still owns at least 126,000 units of ORMP stock.
Oramed Pharmaceuticals key executives
Oramed Pharmaceuticals Inc. executives and other stock owners filed with the SEC:
- Dr. Miriam Kidron Ph.D. (85) Chief Scientific Officer & Director
- Mr. David Silberman (42) Chief Financial Officer, Treasurer & Sec.
- Mr. Joshua Hexter (55) Chief Operating & Bus. Officer
- Mr. Michael Rabinowitz (60) Chief Commercial Officer
- Mr. Nadav Kidron Esq. (51) Pres, Chief Executive Officer & Executive Director